Response to: Comment on 'Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines'.

Abstract

We thank Testori et al. [ [1] Testori A.E. Kunte C. Clover A.J.P. Bechara F.G. Bertino G. Comment on “Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines”. Eur J Canc. 2020; Google Scholar ] for their letter to the Editor related to our published European consensus-based interdisciplinary guidelines on the diagnosis and treatment of basal cell carcinoma (BCC) [ [2] Peris K. Fargnoli M.C. Garbe C. Kaufmann R. Bastholt L. Seguin N.B. et al. European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for research and treatment of cancer (EORTC). Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur J Canc. 2019; 118: 10-34 Abstract Full Text Full Text PDF PubMed Scopus (219) Google Scholar ]. They comment on the role of electrochemotherapy (ECT) as ‘an adjunctive treatment for basal cell carcinoma’ and state that omission of mentioning ECT in the management of patients with BCC in our guidelines should be corrected with a formal addendum [ [1] Testori A.E. Kunte C. Clover A.J.P. Bechara F.G. Bertino G. Comment on “Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines”. Eur J Canc. 2020; Google Scholar ]. They underline that a short paragraph about ECT was included in the EADO guidelines on Kaposi sarcoma, Merkel cell carcinoma and cutaneous squamous cell carcinoma (SCC). Letter to the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization for Research and Treatment of Cancer on guidelines on basal cell carcinomaEuropean Journal of CancerVol. 140PreviewBasal cell carcinoma (BCC) often presents a relatively simple challenge to successfully treat; however, because of an increasingly ageing population with multiple co-morbidities there remains a need to continually evolve and expand the treatment options available for those either unwilling or unsuitable for the established therapies [1]. We, therefore, read with interest the recent publication by Peris et al. [2] (September 2019) in this journal on diagnosis and treatment of basal cell carcinoma, guidelines conceptualised by the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization for Research and Treatment of Cancer. Full-Text PDF Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelinesEuropean Journal of CancerVol. 118PreviewBasal cell carcinoma (BCC) is the most common malignant tumour in white populations. Multidisciplinary experts from the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization of Research and Treatment of Cancer collaborated to develop recommendations on diagnosis and treatment of BCC. A new classification into ‘easy-to-treat (common) BCC and ‘difficult-to-treat’ BCC is proposed. Diagnosis is based on clinicodermatoscopic features for ‘easy-to-treat’ BCCs. Full-Text PDF